Background: The benefits of optimum blood pressure (BP) control in patients with diabetes exceed the benefits of glycaemic control and extend to the prevention of both macro-vascular and micro-vascular complications in patients suffering from both hypertension and diabetes mellitus. Aims & Objective: To investigate the utilization patterns of anti-hypertensive drugs and to evaluate blood pressure (BP) control among diabetic-hypertensive patients with and without reduced renal function. Material and Methods: A prospective, observational study carried out at medicine department of SBKS Medical College and Research Centre, Piparia. The pattern of use of antihypertensive drugs in 50 hypertensive-diabetic patients was evaluated in correlation with its renal function and BP control achieved was compared in patients with and without reduced renal function. Results: Total 63 antihypertensive medication episodes were prescribed for 50 patients. Out of which 76% patients were receiving 1 drug, 22% receiving 2 drugs and 2% receiving 3 drugs of different antihypertensive class. Most patients were receiving Angiotensin-Converting-Enzyme-Inhibitors (ACE-I)/Angiotensin-Receptor-Blockers (ARBs) (60%), followed by CCBs (24%), beta-blockers (20%), and diuretics (16%). Patients on monotherapy were mostly receiving ACE-I/ARB (65.78%). Beta blockers were more commonly prescribed in patients with reduced renal function (p=0.005). BP control was achieved in 63.15% patients in monotherapy and 33.33% in polytherapy group. Control of systolic and diastolic BP was significantly higher in patients without reduced renal function than patients with reduced renal function (p<0.05).
Introduction
Hypertension affects about 20-60% of patients with type-2 diabetes. [1] Serious cardiovascular events are more than twice likely in patients with diabetes and hypertension than either disease alone. [2] The benefits of tight blood pressure (BP) control in patients with diabetes exceed the benefits of tight glycaemic control and extend to the prevention of both macro-vascular and microvascular complications. [3] However, studies consistently demonstrate that most diabetic patients do not achieve recommended levels of BP control, and the majority have a BP of >140/90mmHg. [4] [5] [6] There are a growing number of pharmacological treatment options for patients with hypertension. However, the choice of anti-hypertensive drug class is influenced by many factors such as age, stage of hypertension and the presence of comorbid conditions. The seventh report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC) stated that angiotensin converting enzyme inhibitors (ACE-I) is an important component of most regimens to control BP in diabetic patients. [7] In these patients, ACE-I may be used alone, but are much more effective when combined with thiazide type diuretic or other anti-hypertensive drugs. The JNC seventh report recommended that the BP in diabetics should be controlled to levels of 130/80 mmHg or lower. Rigorous control of BP is paramount for reducing the progression of diabetic nephropathy to end-stage renal disease (ESRD). In hypertensive patients with chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR) < 60 mL/min, the JNC seventh report recommended a goal BP of ≤ 130/80 mmHg and a need for using more than one antihypertensive drug to achieve this goal. [7] Actual drug utilization data in this special group of patients from the local population are very few. Therefore the primary objectives of this study were: 1) to evaluate the utilization of antihypertensive drugs in hypertensive and diabetic patients, 2) to compare utilization of antihypertensive drugs for diabetic patients with reference to renal impairment status and 3) to assess BP control in this population.
Materials and Methods

Settings and Study Design
It was a prospective, observational study carried out at SBKS Medical Institute and Research centre, Piparia, Vadodara. The study protocol was approved by Institutional Ethics Committee (IEC). A total of 50 patients meeting inclusion criteria were enrolled in the study to evaluate the pattern of use of antihypertensive drugs in patients suffering from both diabetes mellitus and hypertension and its correlation with reduced renal function. All the patients were explained clearly about the nature and purpose of the study in the language they understand and consent was obtained before enrolling them for the study. Records of inpatients and outpatients from medicine department were collected.
Inclusion Criteria & Exclusion Criteria
Diabetic hypertensive patients of either sex and any age attending medicine OPD and/or admitted in medicine ward and patients willing to participate in the study were enrolled in the study while patients with any cardiovascular complication, like ischaemic heart disease (IHD), chronic heart failure (CHF) or renal complication like end stage renal disease (ESRD) etc. and seriously ill patients requiring ICU admission or stay were excluded from study.
Sample Size
The primary objective of the study was to evaluate the pattern of antihypertensive drug use among diabetic hypertensive patients. Assuming a prevalence rate of hypertension in diabetic patient as 70% [1] and taking allowable error as 20% of positive character, 42 patients were needed to give an estimate at a width of 5% and with 95% confidence interval. Therefore 50 patients were enrolled for the present study. [8] 
Participants & Data Collection
All the patients were examined on the day of enrolment in study and relevant details like past and present history of disease, blood pressure, serum creatinine and random blood sugar (RBS), drug therapy used etc were noted in the structured case record form by the researcher. The primary researcher was the doctor but not involved in any therapeutic decision for the patients. Patients were visited once only on the day of enrolment. Patients were interviewed for about 10-20 minutes and past as well as present hospital records were referred for gathering necessary information. All the data was analysed subsequently for different drugs used for hypertension with respect to presence of renal function impairment as measured by creatinine clearance.
Outcome Measure
The achievement of target blood pressure (≤130/80mmhg) was taken as a primary outcome measure. Different antihypertensive drugs used & their correlation with renal function and impact on target blood pressure achievement was also evaluated. For the present study, Elevated or nontarget BP was defined as greater than or equal to 130/80 mmHg, according to the JNC seventh report. [7, 9] Reduced renal function or renal impairment was defined as creatinine clearance (Cr Cl) ≤ 60 mL/min or glomerular filtration rate GFR < 60 mL/ min. Creatinine clearance and GFR were calculated from the serum creatinine levels using a Cockcroft-Gault equation. [9] Statistical Analysis Data were presented as actual frequencies, percentage, mean and standard deviation. Analysis was carried out using Microsoft excel 2010 version and chi-square test, "p" values equal to or less than 0.05 was considered as significant.
Results
A total of 50 participants were enrolled in the study meeting inclusion criteria, out of which 26 (52%) were males and 24 (48%) were females. The mean age (SD) of the patients was 56.04 ± 10.46 years. The most recently recorded values of systolic, diastolic BP and random blood glucose level were 151.17 ± 29.40; 86.22 ± 13.06 and 173.4 ± 65.38 mg/dl respectively. The mean serum creatinine of the patients was 1.21 ± 0.66 mL/min with Glomerular filtration rate (GFR) 76.9 ± 29.16 mL/min. Out of total 50, 19 patients (38%) had reduced renal function GFR < 60 mL/min. The recommended target BP of equal or lower than 130/80 mmHg was achieved in 28(56%) patients with drug therapy. Duration of hypertension was <1 year in 44% of cases, 1-2 years in 18% of cases, >3 years in 38% of cases with the mean of 1.88 ± 1.52 years which does not positively correlates with status of kidney function (p=0.11). Clinical and demographic characteristics of the study population are shown in table 1.
A total of 63 antihypertensive medication episodes were prescribed for 50 patients. Out of 50 patients, 38 (76%) were receiving 1 drug, 11 (22%) were receiving 2 drugs and 1 (2%) was receiving 3 drugs of different antihypertensive class. Most patients were receiving angiotensin converting enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs) 30 antihypertensive episode (60%), followed by calcium channel blockers (CCBs) (12, 24%), beta blockers (10, 20%), and diuretics (8, 16%). Patients on monotherapy were mostly receiving ACE-I/ARB (25, 65.78%) followed by beta blockers (5, 13.15%), CCBs (4, 0.52%), thiazide diuretics (2, 5.26%) and combined alpha and beta blocker 2 patients (5.26%). [ Table 2 ] Out of total 50 patient, 9 (18%) were prescribed fixed dose combination (FDCs). Most common prescribed combination were amlodipine/ atenolol in strength of 5/50 mg and losartan/hydrochlorthiazide 50/ 12.5 mg each of which was given to 4 (44.44%) out of 9 patients. Only 1 patient was given metoprolol/amlodipine combination. Multi drug therapy was given to total 11 (22%) patients. Most common combination was CCB + beta blocker (5 patients), followed by ARB + Diuretic (3 patients), CCB + Diuretic (2 patients), ARB + CCB and ARB + Diuretic + combined alpha and beta blocker (1 patient each). The prescription of multi drug therapy did not differ significantly among patients with or without reduced renal function (P>0.05).
Discussion
This study investigated the patterns of antihypertensive drug therapy in diabetichypertensive patients with and without renal impairment. This study showed that one-third (19, 38%) of the total patients had reduced renal function (GFR< 60 mL/min) suggesting that screening for renal function among diabetic hypertensive patients and implementing rigorous therapy is important to delay progression to complications like end stage renal disease (ESRD).
This study revealed that 76% of the total patients were on single drug therapy, 22% were on two drugs, 2% were on three drugs therapy which differs from study done by Johnson et al where monotherapy was prescribed to 23.7%, 2 drugs were given to 24%, 3 and 4 drugs 18% and 15.2% of patients respectively. [10] Our patients were overall prescribed less antihypertensive medicines than western population. ACE-I/ARB was the most commonly prescribed drug class both in mono and combination therapy. The reported mono and combination use of ACE-I was 47.61% which is lower than that reported by Johnson et al in treating diabetic-hypertensive patients.
[10] ACE-I prevents microvascular complications and can prevent progression of renal damage and also ESRD in addition to lowering BP. [7] Thus our practice coincides very well with evidence base JNC 7 th guideline.
CCBs ranked second followed by beta blocker and diuretics when considering overall utilization of various anti-hypertensive drugs which differs from results of study done by Johnson et al where thiazide was second most frequently prescribed drug followed by CCBs and beta blocker. 10 The study done by Sweileh et al also showed similar utilization pattern considering overall utilization various classes. [11] The prescription of multi drug therapy did not differ significantly among patients with or without reduced renal function. This is not in agreement with the JNC recommendation which emphasizes the role of combination therapy in this particular category of patients to delay progression to ESRD. Most commonly prescribed combinations were CCB with Beta blocker and ACE-I with diuretic. In combination of CCB and beta blocker, amlodipine was prescribed CCB along with atenolol as a betablocker. The combination of this drug provides added advantage because of both drugs have a different mechanism of action for reduction in blood pressure. They are also beneficial in nullifying adverse effects of each other as tachycardia caused by beta blocker is counteract by beta blockers. [12] ACE-I and thiazide combination is pharmacologically favourable since it produces an additive anti-hypertensive effect and minimizes most adverse effects of either the ACE-I or the diuretics, especially hypokalemia. [13] Even guidelines also suggests that patient with chronic kidney disease should receive ACE-I/ARB in combination with diuretic. [7] The importance of the diuretic agent was also emphasized by the "Anti-hypertensive and LipidLowering Treatment to Prevent Heart Attack Trial", ALLHAT study. [14] There was no significant difference found in use of various antihypertensive drug class (p>0.05) in both the group, except patients with reduced renal function were more frequently prescribed beta blocker than patients without reduced renal function (p<0.001). In this study beta blockers were third most common group prescribed which is not coinciding with other studies Johnson et al in USA and Sweileh WM et al in Palestine. [10, 11] This suggests that there is a scope for improvement in prescribing in diabetic hypertensive patients in Indian set up. The reason for more use of beta blockers in patients with reduced renal function in this study needs further evaluation.
This study also showed that there was significant difference in control of systolic as well diastolic blood pressure in patients without reduced renal function than in patients with reduced renal function. Better blood pressure control in this group is might be due to their good kidney function.
It is most important to achieve recommended blood pressure control in diabetic hypertensive patient with renal impairment. Many studies have shown to achieve this control in accordance to guidelines of JNC 7 with use of different antihypertensive medications in combination. Similar studies conducted by a research group Khaja et al at Bahrain on patients with type-2 DM and HTN showed that the prescribing patterns of antihypertensive medications differ in many instances from the World Health Organization guidelines especially, regarding the choices and drug combinations of anti-hypertensive drugs. [15] This study has certain limitations like patients were not followed up for the gathering detailed and long term information on BP control achieved and occurrence of complications. Moreover the sample size was also small though adequate by calculation of prevalence. Larger studies involving different age groups and large number of patients are required to implement these findings to general population of India.
This study has provided a snapshot insight into actual use of antihypertensive medicines in patients with diabetes with regard to their renal function. We conclude from this study that there was a suboptimum use of combination therapy among diabetic-hypertensive patients in general. Furthermore, diabetic-hypertensive patients with renal impairment were not given intensive antihypertensive therapy compared to patients with normal renal function as reflected by control achieved in systolic and diastolic BP. We recommend efficient drug use in this special group of patients. Education of health-care providers regarding appropriate and rational use of antihypertensive can help in better management of these patients. There is also a need to form guidelines at national and state level for management of these patients.
Conclusion
There was suboptimum use of combination therapy among diabetic-hypertensive patients in general and specifically in developing countries as reflected by control achieved in systolic and diastolic BP which requires concern of all healthcare professionals.
